切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2019, Vol. 09 ›› Issue (03) : 144 -148. doi: 10.3877/cma.j.issn.2095-1221.2019.03.003

所属专题： 文献；

论著

利拉鲁肽联合二甲双胍对2型糖尿病合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响
张红敏1, 吴锦林2, 张兴渝1, 杨媚1,†()   
  1. 1. 401121　重庆两江新区第一人民医院内分泌科
    2. 400021　重庆市中医院内分泌科
  • 收稿日期:2019-04-24 出版日期:2019-06-01
  • 通信作者: 杨媚
  • 基金资助:
    重庆市卫生计生委医学科研计划资助项目(2015MSXM213)

Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity

Hongmin Zhang1, Jinlin Wu2, Xingyu Zhang1, Mei Yang1,†()   

  1. 1. Department of Endocrinology of First People's Hospital of Chongqing Liangjiang New District, Chongqing 401121, China
    2. Department of Endocrinology of Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China
  • Received:2019-04-24 Published:2019-06-01
  • Corresponding author: Mei Yang
  • About author:
    Corresponding author: Yang Mei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张红敏, 吴锦林, 张兴渝, 杨媚. 利拉鲁肽联合二甲双胍对2型糖尿病合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响[J]. 中华细胞与干细胞杂志(电子版), 2019, 09(03): 144-148.

Hongmin Zhang, Jinlin Wu, Xingyu Zhang, Mei Yang. Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(03): 144-148.

目的

分析利拉鲁肽联合二甲双胍对2型糖尿病（T2DM）合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响。

方法

选取重庆两江新区第一人民医院2016年3月至2018年3月收治的194例T2DM合并肥胖患者，将其随机分为研究组、对照组，各97例，均给予为期16周的二甲双胍治疗，研究组加用利拉鲁肽皮下注射。比较两组患者治疗前后血糖、胰岛β细胞功能指数（HOMA-β）、内脏脂肪水平（VFL）等指标变化，总结利拉鲁肽在T2DM合并肥胖治疗中的临床价值。计数资料采用卡方检验，计量资料采用t检验。

结果

研究组不良反应发生率为29.90﹪，对照组为23.71﹪，组间比较差异无统计学意义（χ2= 0.946，P > 0.05）。两组患者治疗后FPG、2 hPG、BMI均较治疗前下降，研究组治疗后FPG、2 hPG、BMI分别为（7.12±1.35）?mmol/?L、（9.03±2.66）?mmol/L、（26.32±1.60）kg/m2，均低于对照组的（7.83± 1.19）?mmol/L、（10.57±2.39）?mmol/?L、（27.74±1.66）kg/m2，差异有统计学意义（t = 3.886、4.241、6.066，P均?< 0.05）。两组患者治疗后HOMA-β较治疗前升高，HOMA-IR较治疗前下降，研究组治疗后HOMA-β为155.69±24.55，高于对照组的117.49±21.98，其HOMA-IR为2.30±0.71，低于后者的3.20±0.64，差异有统计学意义（t = 11.407、9.273，P均< 0.05）。两组患者治疗后VFL、脂肪率均较治疗前下降，研究组治疗后VFL、脂肪率低于对照组，且其治疗后肌肉含量较治疗前下降，差异有统计学意义（P < 0.05）。

结论

在二甲双胍的基础上联合利拉鲁肽能够通过改善胰岛β细胞功能、减少内脏脂肪，达到改善T2DM合并肥胖患者的胰岛素抵抗的目的，是一种安全、有效的治疗方案。

关键词: 利拉鲁肽, 二甲双胍, 2型糖尿病, 肥胖, 胰岛β细胞, 内脏脂肪
Objective

To analyze the effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus (T2DM) patients with obesity.

Methods

194 patients with T2DM and obesity admitted to our hospital from March 2015 to March 2018 were randomly divided into a study group and a control group (97 cases in each group) . All patients were treated with metformin for 16 weeks. The study group was treated with liraglutide subcutaneously. The changes of blood sugar, pancreatic beta cell function index (HOMA-β) and visceral fat level (VFL) before and after treatment were compared between the two groups, and the clinical value of liraglutide in the treatment of T2DM with obesity was summarized. Chi-square test was used for counting data and t-test was used for measuring data.

Results

The incidence of adverse reactions was 29.90﹪ in the study group and 23.71﹪ in the control group. There was no significant difference between the two groups (χ2= 0.946, P > 0.05) . After treatment, FPG, 2 hPG and BMI of the two groups were all lower than those before treatment, and FPG, 2hPG and BMI in the study group were (7.12±1.35) mmol/L, (9.03±2.66) mmol/L, (26.32±1.60) kg/m2, respectively, which were lower than those in the control group (7.83±1.19) mmol/L, (10.57±2.39) ?mmol/?L, (27.74±1.66) ?kg/m2, (t = 3.886, 4.241, 6.066, P all < 0.05) . After treatment, HOMA-beta was increased and HOMA-IR was decreased in both groups. After treatment, HOMA-beta in the study group (155.69±24.55) was, higher than that in the control group (117.49±21.98) , and its HOMA-IR (2.30±0.71) was lower than that in the latter group (3.20±0.64) . The difference was statistically significant (t = 11.407, 9.273, P all < 0.05) . The VFL and fat rate of the two groups after treatment were lower than those before treatment. The VFL and fat rate of the study group after treatment were lower than those of the control group, and the muscle content after treatment was lower than that before treatment (P < 0.05) .

Conclusion

Combination of liraglutide with metformin can improve insulin resistance in patients with T2DM and obesity by improving the function of islet beta cells and reducing visceral fat, which is a safe and effective treatment.

Key words: Liraglutide, Metformin, Type 2 diabetes mellitus, Obesity, Islet beta cells, Visceral fat
表1 两组患者治疗前后血糖水平及BMI变化比较（n = 97，±s）
分组 FPG （mmol/L） 2 hPG （mmol/L） BMI （kg/m2）
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 9.71±1.98 7.12±1.35 10.644 < 0.01 14.76±2.33 9.03±2.66 15.959 < 0.01 29.44±1.92 26.32±1.60 12.295 < 0.01
对照组 9.80±1.72 7.83±1.19 9.277 < 0.01 14.58±2.47 10.57±2.39 11.491 < 0.01 29.12±1.85 27.74±1.66 5.468 < 0.01
t值 0.338 3.886 ? ? 0.522 4.241 ? ? 1.182 6.066 ? ?
P值 0.368 < 0.01 ? ? 0.301 < 0.01 ? ? 0.119 < 0.01 ? ?
表2 两组患者治疗前后胰岛β细胞功能相关指标变化比较（n = 97，±s）
分组 HOMA-β HOMA-IR
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 102.26±21.37 155.69±24.55 16.168 < 0.01 3.76±1.05 2.30±0.71 11.344 < 0.01
对照组 105.03±20.26 117.49±21.98 4.095 < 0.01 3.71±0.99 3.20±0.64 4.261 < 0.01
t值 0.926 11.407 ? ? 0.000 9.273 ? ?
P值 0.178 < 0.01 ? ? 0.500 < 0.01 ? ?
表3 两组患者治疗前后体成分变化比较（n = 97，±s）
分组 VFL 脂肪率（﹪） 肌肉含量（kg）
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 13.15±2.06 9.06±1.81 14.690 < 0.01 32.35±3.17 27.05±2.23 13.468 < 0.01 43.35±8.16 45.49±8.02 1.842 0.033
对照组 13.07±1.95 10.12±1.63 11.432 < 0.01 32.66±3.25 29.72±4.03 5.593 < 0.01 43.71±9.05 44.80±9.27 0.829 0.204
t值 0.278 4.286 ? ? 0.673 5.709 ? ? 0.291 0.554 ? ?
P值 0.391 < 0.01 ? ? 0.251 < 0.01 ? ? 0.386 0.290 ? ?
[1]
廖涌. 中国糖尿病的流行病学现状及展望[J]. 重庆医科大学学报, 2015, 40(7):1042-1045.
[2]
Mann JF,Orsted DD,Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(9):839-848.
[3]
Davies MJ,Bergenstal R,Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes the SCALE diabetes randomized clinical trial[J]. JAMA, 2015, 314(7):687-699.
[4]
Pi-Sunyer X,Astrup A,Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management[J]. N Engl J Med, 2015, 373(1):11-22.
[5]
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J/ CD]. 中国医学前沿杂志(电子版), 2015, 30(3):26-89.
[6]
Armstrong MJ,Gaunt P,Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(119):679-690.
[7]
le Roux CW,Astrup A,Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes:a randomised,double-blind trial[J]. Lancet, 2017, 389(10077):1399-1409.
[8]
Dejgaard TF,Frandsen CS,Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control(Lira-1):a randomised,double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2016, 4(3):221-232.
[9]
Ahren B,Hirsch IB,Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial[J]. Diabetes Care, 2016, 39(10):1693-1701.
[10]
Iacobellis G,Mohseni M,Bianco SD, et al. Liraglutide causes large and rapid epicardial fat reduction[J]. Obesity, 2017, 25(2):311-316.
[11]
郭洁,孙耀东,边亚, 等. 观察利拉鲁肽对糖尿病病人血脂和超敏C-反应蛋白的影响[J]. 中西医结合心脑血管病杂志, 2016, 14(17):2055-2057.
[12]
Blackman A,Foster GD,Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial[J]. Int J Obes, 2016, 40(8):1310-1319.
[13]
Rizzo M,Abate N,Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes:a prospective pilot study[J]. J Clin Endocrinol Metab, 2015, 100(2):603-606.
[14]
刘琼,卫家芬. 利拉鲁肽治疗糖尿病的研究进展[J]. 河北医药, 2015, 37(5):732-734.
[15]
Santilli F,Simeone PG,Guagnano MT, et al. Effects of liraglutide on weight loss, fat distribution,and β-cell function in obese subjects with prediabetes or early type 2 diabetes[J]. Diabetes Care, 2017, 40(11):1556-1564.
[16]
Farr OM,Sofopoulos M,Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled[J]. Diabetologia, 2016, 59(5):954-965.
[17]
蒙光义,彭评志,庞家莲, 等. 利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效和安全性评估[J]. 医学综述, 2015, 21(17):3223-3226.
[18]
Gao DM,Bao SD. Regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity[J]. Journal of Hainan Medical University, 2017, 23(16):37-40.
[19]
Lingvay I,Desouza CV,Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin[J]. Diabetes Care, 2018, 41(9):1926-1937.
[20]
Billings LK,Doshi A,Gouet D, et al. Efficacy and safety of IDegLira versus Basal-Bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5):1009-1016.
[1] 何金梅, 尹立雪, 谭静, 张文军, 王锐, 任梅, 廖明娇. 超声心肌做功技术对2型糖尿病患者潜在左心室心肌收缩功能损伤的评价[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1029-1035.
[2] 李永浩, 高雪菲, 郭田田, 张进, 张彩针, 刘静. 肥胖合并甲状腺癌相关机制的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 311-315.
[3] 纪凯伦, 郝少龙, 孙海涛, 韩威. 减重术后胆囊结石形成机制的新进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 100-103.
[4] 陈大敏, 曹晓刚, 曹能琦. 肥胖对胃癌患者手术治疗效果的影响研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 651-653.
[5] 聂锋, 李婉珍. 不打针不吃药不输液徒手治疗糖尿病一例报道[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 354-354.
[6] 向承红, 刘伟, 耿苗苗, 张海泳. 肥胖患者腹壁巨大切口疝腹腔镜手术配合中精准化管理与应用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(03): 334-336.
[7] 张政赢, 鞠阳, 刘晓宁. 二甲双胍对2型糖尿病患者大肠腺瘤术后复发的影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 485-488.
[8] 薛念余, 张盛敏, 吴凌恒, 沙蕾, 童揽月, 沈崔琴, 李朝军, 杜联芳. 研究血清胆红素对2型糖尿病患者心脏结构发生改变前心肌功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1004-1009.
[9] 陶璐, 初楠, 韩洁, 白春英, 逄雯丽, 余海源. 血清PECAM-1、Sirt1水平与2型糖尿病患者颈动脉粥样硬化的关系[J]. 中华临床医师杂志(电子版), 2023, 17(03): 291-296.
[10] 韩家超, 王飞飞, 柳子宁, 胡冀陶, 孟泽松, 雒月云, 王贵英. 二甲双胍的作用机制研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(03): 349-355.
[11] 高文星, 刘浩, 赵稳, 李丁昌, 陈鹏, 金露佳, 刘先强, 董光龙. 减重手术后慢性腹痛的原因与对策[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 149-154.
[12] 汪赓, 夏泽锋, 陶凯雄. 代谢手术在非肥胖型2型糖尿病中的治疗效果及研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 155-160.
[13] 马俊蓉, 叶艳彬. 减重手术后的营养管理与复胖：现状与思考[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 165-172.
[14] 范晓轩, 王娜, 朱丽花, 王亮. 肥胖相关肿瘤研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 173-178.
[15] 李锦亮, 曾茂娟, 钟金宝, 何伟强, 林文新. 司美格鲁肽对肥胖2型糖尿病患者皮肤微循环功能的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 192-196.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号